



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade:	77.66
Trade Time:	4:00 PM ET May 23, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	74.13 - 147.17
Volume	14,399

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID<sup>®</sup>, VIDAZA<sup>®</sup>, THALOMID<sup>®</sup>, POMALYST<sup>®</sup>/IMNOVID<sup>®</sup>, ABRAXANE<sup>®</sup>, OTEZLA<sup>®</sup>, ISTODAX<sup>®</sup> and IDHIFA<sup>®</sup>. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

May 24, 2018  
[Celgene Corporation Announces Additional \\$3 Billion Share Repurchase Authorization and Plans to Execute a \\$2 Billion Accelerated Share Repurchase Program](#)

May 22, 2018  
[Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018](#)

May 16, 2018  
[Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology \(ASCO\) Scientific Sessions](#)

May 14, 2018  
[Celgene Corporation to Webcast at Upcoming Investor Conferences and Events](#)

May 4, 2018  
[Celgene Reports First Quarter 2018 Operating and Financial Results](#)

## Upcoming Events [\[ View all \]](#)

May 24, 2018 1:30 PM ET  
[R&D Deep Dive on Multiple Myeloma](#)

May 30, 2018 3:00 PM ET  
[Bernstein Thirty-Fourth Annual Strategic Decisions Conference 2018](#)

## Financials [\[ View all \]](#)

Feb 7, 2018  
[Annual Report \(10-K\)](#)

Apr 30, 2018  
[Proxy Statement \(DEF 14A\)](#)

May 4, 2018  
[Quarterly Report \(10-Q\)](#)

Oct 26, 2017  
[Quarterly Report \(10-Q\)](#)

Jul 27, 2017  
[Quarterly Report \(10-Q\)](#)